Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine for the treatment of MSI-H solid tumors

 In Press Releases

Results presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

BASEL, Switzerland – 10th November 2021 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced that promising interim safety, immunogenicity, pharmacokinetic, pharmacodynamic, and clinical activity data from the Phase 1 trial evaluating NOUS-209 will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-14, 2021). NOUS-209 is an off-the-shelf cancer vaccine based on shared neoantigens, administered in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of Microsatellite Instable High (MSI-H) gastric, colorectal and gastro-esophageal junction solid tumors.

Dr Michael Overman, MD Principal Investigator (PI) of the trial and Professor in the Department of Gastrointestinal Medicine at the University of Texas MD Anderson Cancer Center, said: “It is really encouraging to see these interim Phase 1 data presented at SITC build positively and add to the initial results seen a couple of months ago at ESMO. These data, now obtained from 12 metastatic MSI-H GI patients, show that NOUS-209 continues to demonstrate a favorable safety profile, high levels of vaccine immunogenicity and early signs of clinical efficacy.”

Dr Marina Udier, Chief Executive Officer of Nouscom, added: “We are extremely pleased with the continued safety and tolerability profile of NOUS-209 and the convincing evidence of strong immunogenicity in metastatic cancer patients. The increase in effector CD8 T cells and decrease in Tregs seen in tumor biopsies of responding patients and the signs of durable clinical efficacy in multiple metastatic patients, including one in clinical remission, is exciting early evidence highlighting the potential of NOUS-209. We look forward to further data from this trial to support the development of NOUS-209 as potentially the first neoantigen off-the-shelf cancer vaccine targeting MSI-H tumors.”

Poster Presentation Details:

  • Title: Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability (dMMR/MSI) (#410)
  • Date: 13th November 2021
  • Time: 12:30-14:00 and 19:00-20:30 EST
  • Location: Poster Hall, Walter E. Washington Convention Center, Washington, D.C.
  • Presenter: Dr Dung Thi Le, MD, Senior Investigator of the trial and Professor of Oncology at the John Hopkins University School of Medicine

The abstracts will be publicly available at 8am EST on 9th November 2021, and available in the Journal for ImmunoTherapy of Cancer (JITC) supplement.

Recent Posts
error: Content is protected !!!